Compare · NVO vs RNAZ
NVO vs RNAZ
Side-by-side comparison of Novo Nordisk A/S (NVO) and TransCode Therapeutics Inc. (RNAZ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and RNAZ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $220.35B, about 7522.1x RNAZ ($29.3M).
- Over the past year, NVO is down 34.2% and RNAZ is down 15.7% - RNAZ leads by 18.5 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 0 for RNAZ).
- Company
- Novo Nordisk A/S
- TransCode Therapeutics Inc.
- Price
- $41.18+6.93%
- $9.94+20.48%
- Market cap
- $220.35B
- $29.3M
- 1M return
- +13.32%
- +15.45%
- 1Y return
- -34.24%
- -15.69%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 5
- 5
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S
Latest RNAZ
- SEC Form SCHEDULE 13G filed by TransCode Therapeutics Inc.
- SEC Form 10-K filed by TransCode Therapeutics Inc.
- SEC Form DEFA14A filed by TransCode Therapeutics Inc.
- TransCode Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028
- SEC Form NT 10-K filed by TransCode Therapeutics Inc.
- SEC Form DEFA14A filed by TransCode Therapeutics Inc.
- TransCode Therapeutics Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients
- TransCode Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits